Teva Pharmaceuticals (NYSE:TEVA) announced today that it appointed Dr. Eric A. Hughes as VP of global R&D and chief medical officer.
Hughes’ employment becomes effective Aug. 1, 2022, and he will be based out of Tel Aviv, Israel-based Teva’s U.S. headquarters in Parsippany, New Jersey.
Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.